Literature DB >> 16813883

Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.

Wolfgang Schäfer1, Peter-Jörg Funke, Dieter Kunde, Ulrich Rausch, Gunther Wennemuth, Hartmut Stützer.   

Abstract

PURPOSE: We analyzed the potential prognostic significance of the immunohistochemical expression of androgen and growth factor receptors determined in prostatectomy specimens of patients with prostate cancer.
MATERIALS AND METHODS: A cohort of 211 patients with locally confined prostate cancer treated with radical prostatectomy with or without antiandrogen pretreatment between January 1, 1990 and August 31, 1996 was observed prospectively. Prostatectomy samples were processed immunohistochemically to visualize androgen and growth factor receptors, of which immunoreaction intensity was scored relative to that of positive control tissue. Clinical postoperative data were processed using the Kaplan-Meier method, log rank test, and univariate and multivariate explorative Cox modeling to evaluate the contribution to overall and relapse-free survival.
RESULTS: There were statistical dependencies between the androgen receptor and epidermal growth factor receptor staining indexes. Following data stratification according to the epidermal growth factor receptor staining index the prognosis associated with a low androgen receptor staining index was worse than that with a higher androgen receptor staining index. Cox regression analysis for relapse-free survival confirmed that the risk factors low androgen receptor and increased epidermal growth factor receptor staining were associated with significantly increased relative risk. Univariate Kaplan-Meier analysis showed that patients with grade 3 carcinoma had a worse prognosis than those with better differentiated carcinoma, whereas antiandrogen pretreatment had no influence on overall survival or relapse-free survival.
CONCLUSIONS: Using a multivariate proportional hazards regression model for data on a cohort of 211 patients with 68 showing relapse/progress or death from disease a low intensity of androgen receptor staining indicated a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16813883     DOI: 10.1016/j.juro.2006.03.033

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

Review 2.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 3.  Molecular staging of prostate cancer in the year 2007.

Authors:  Thorsten Schlomm; Andreas Erbersdobler; Martina Mirlacher; Guido Sauter
Journal:  World J Urol       Date:  2007-03-02       Impact factor: 4.226

Review 4.  Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-03-17

Review 5.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

6.  Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas.

Authors:  Bernd W Scheithauer; Kalman Kovacs; Suzan Zorludemir; Ricardo V Lloyd; Seyda Erdogan; Jeffrey Slezak
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

7.  Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.

Authors:  Murielle Mimeault; Sonny L Johansson; Surinder K Batra
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

Review 8.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

9.  PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.

Authors:  Khalil Choucair; Joshua Ejdelman; Fadi Brimo; Armen Aprikian; Simone Chevalier; Jacques Lapointe
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

10.  Ebp1 expression in benign and malignant prostate.

Authors:  Philippe O Gannon; Ismaël Hervé Koumakpayi; Cécile Le Page; Pierre I Karakiewicz; Anne-Marie Mes-Masson; Fred Saad
Journal:  Cancer Cell Int       Date:  2008-11-24       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.